Ever Supreme Bio Technology Past Earnings Performance
Past criteria checks 5/6
Ever Supreme Bio Technology has been growing earnings at an average annual rate of 63.4%, while the Biotechs industry saw earnings growing at 17.8% annually. Revenues have been growing at an average rate of 59.7% per year. Ever Supreme Bio Technology's return on equity is 29.3%, and it has net margins of 71.1%.
Key information
63.4%
Earnings growth rate
63.3%
EPS growth rate
| Biotechs Industry Growth | 12.2% |
| Revenue growth rate | 59.7% |
| Return on equity | 29.3% |
| Net Margin | 71.1% |
| Next Earnings Update | 08 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Ever Supreme Bio Technology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 758 | 539 | 48 | 99 |
| 30 Sep 23 | 683 | 571 | 45 | 95 |
| 30 Jun 23 | 628 | 335 | 41 | 95 |
| 31 Mar 23 | 621 | 326 | 40 | 90 |
| 31 Dec 22 | 628 | 201 | 40 | 91 |
| 30 Sep 22 | 603 | 153 | 45 | 97 |
| 30 Jun 22 | 575 | 348 | 45 | 85 |
| 31 Mar 22 | 513 | 374 | 43 | 87 |
| 31 Dec 21 | 439 | 370 | 45 | 84 |
| 30 Sep 21 | 310 | 261 | 39 | 79 |
| 30 Jun 21 | 193 | 15 | 36 | 90 |
| 31 Mar 21 | 112 | -94 | 35 | 100 |
| 31 Dec 20 | 71 | -107 | 30 | 109 |
| 30 Sep 20 | 53 | -118 | 42 | 119 |
| 30 Jun 20 | 28 | -124 | 43 | 110 |
| 31 Mar 20 | 19 | -102 | 43 | 100 |
| 31 Dec 19 | 11 | -94 | 43 | 95 |
| 30 Sep 19 | 2 | -80 | 30 | 89 |
| 30 Jun 19 | 0 | -85 | 29 | 92 |
| 31 Mar 19 | 0 | -77 | 25 | 83 |
| 31 Dec 18 | 0 | -69 | 21 | 73 |
| 30 Sep 18 | 0 | -56 | 17 | 60 |
| 30 Jun 18 | 0 | -43 | 13 | 46 |
| 31 Mar 18 | 0 | -37 | 12 | 38 |
| 31 Dec 17 | 0 | -31 | 11 | 29 |
Quality Earnings: 6712 has a high level of non-cash earnings.
Growing Profit Margin: 6712's current net profit margins (71.1%) are higher than last year (32%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6712 has become profitable over the past 5 years, growing earnings by 63.4% per year.
Accelerating Growth: 6712's earnings growth over the past year (168.7%) exceeds its 5-year average (63.4% per year).
Earnings vs Industry: 6712 earnings growth over the past year (168.7%) exceeded the Biotechs industry -13.8%.
Return on Equity
High ROE: 6712's Return on Equity (29.3%) is considered high.